PE20211638A1 - Piridopirimidinas como inhibidores del receptor de histamina h4 - Google Patents

Piridopirimidinas como inhibidores del receptor de histamina h4

Info

Publication number
PE20211638A1
PE20211638A1 PE2021000096A PE2021000096A PE20211638A1 PE 20211638 A1 PE20211638 A1 PE 20211638A1 PE 2021000096 A PE2021000096 A PE 2021000096A PE 2021000096 A PE2021000096 A PE 2021000096A PE 20211638 A1 PE20211638 A1 PE 20211638A1
Authority
PE
Peru
Prior art keywords
histamine
pyrido
diseases
compounds
pyrimidin
Prior art date
Application number
PE2021000096A
Other languages
English (en)
Inventor
Herrero Gonzalo Hernandez
Dominguez Neftali Garcia
Arce Arturo Zazpe
Tizne Roberto Olivera
Pedro Barbara Noverges
Vivar Reyes Corcostegui
Cerdeiras Paloma Tato
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of PE20211638A1 publication Critical patent/PE20211638A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Esta referido a derivados de pirido[3,4-d]pirimidina de Formula I, en donde: R1 es H, halogeno, alquilo, entre otras opciones; R2 es alquilo, cicloalquilo, arilo, arilalquilo; R3 es heterociclilo, NR18R19; X es O, NR6. Entre los compuestos preferidos tenemos los siguientes: 6-cloro-2-(1,2,3,6-tetrahidropiridin-4-il)-N-(tiofen-2-ilmetil)pirido[3,4- d]pirimidin-4-amina; 2-((6-cloro-2-(piperazin-1-il)pirido[3,4-d]pirimidin-4-il)amino)-N-feniletano1-sulfonamida; entre otros. Estos compuestos muestran actividad como antagonistas del receptor de histamina H4 y son utiles en el tratamiento de trastornos y enfermedades mediados por este receptor. Tambien se ha encontrado que los compuestos tambien pueden ser activos como antagonistas del receptor de histamina H1, y por tanto pueden inhibir ambos receptores de histamina. Esta doble inhibicion proporciona un efecto mejorado en enfermedades y trastornos en los que ambos receptores estan implicados, tales como enfermedades alergicas de tipo I.
PE2021000096A 2018-07-25 2019-07-24 Piridopirimidinas como inhibidores del receptor de histamina h4 PE20211638A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382559 2018-07-25
PCT/EP2019/069905 WO2020020939A1 (en) 2018-07-25 2019-07-24 Pyridopyrimidines as histamine h4-receptor inhibitors

Publications (1)

Publication Number Publication Date
PE20211638A1 true PE20211638A1 (es) 2021-08-24

Family

ID=63207688

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000096A PE20211638A1 (es) 2018-07-25 2019-07-24 Piridopirimidinas como inhibidores del receptor de histamina h4

Country Status (27)

Country Link
US (1) US20210300922A1 (es)
EP (1) EP3827005B1 (es)
JP (1) JP7093462B2 (es)
KR (1) KR102603203B1 (es)
CN (1) CN112739699B (es)
AU (1) AU2019310889B2 (es)
BR (1) BR112021001270A2 (es)
CA (1) CA3107556C (es)
CL (1) CL2021000184A1 (es)
CO (1) CO2021001925A2 (es)
DK (1) DK3827005T3 (es)
EA (1) EA202190339A1 (es)
EC (1) ECSP21010874A (es)
ES (1) ES2929227T3 (es)
HR (1) HRP20221250T1 (es)
HU (1) HUE059824T2 (es)
LT (1) LT3827005T (es)
MA (1) MA53372B1 (es)
MX (1) MX2021000966A (es)
PE (1) PE20211638A1 (es)
PH (1) PH12021550143A1 (es)
PL (1) PL3827005T3 (es)
PT (1) PT3827005T (es)
RS (1) RS63661B1 (es)
SG (1) SG11202100575QA (es)
WO (1) WO2020020939A1 (es)
ZA (1) ZA202101092B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021014116A (es) * 2019-05-31 2021-12-10 Chiesi Farm Spa Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3).
JP2023084709A (ja) * 2020-04-28 2023-06-20 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 ヒスタミンｈ４受容体調節作用を有する新規二環化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2577275A1 (en) 2004-08-31 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors
JP2008280341A (ja) 2007-04-12 2008-11-20 Sumitomo Chemical Co Ltd ヒドラジド化合物およびその防除用途
EP2077263A1 (en) 2008-01-02 2009-07-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Quinazolines and related heterocyclic compounds and their therapeutic use
RU2011116928A (ru) * 2008-09-30 2012-11-20 Астразенека Аб (Se) Гетероциклические ингибиторы jак киназы
EP2270002A1 (en) 2009-06-18 2011-01-05 Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg Quinazoline derivatives as histamine H4-receptor inhibitors for use in the treatment of inflammatory disorders
US20110319409A1 (en) * 2010-06-23 2011-12-29 Cox Christopher D 7-aza-quinazoline pde10 inhibitors
BR112015007061B1 (pt) * 2012-09-28 2022-10-04 Cancer Research Technology Limited Composto, composição farmacêutica e uso do composto

Also Published As

Publication number Publication date
JP7093462B2 (ja) 2022-06-29
US20210300922A1 (en) 2021-09-30
RS63661B1 (sr) 2022-11-30
ES2929227T3 (es) 2022-11-25
CL2021000184A1 (es) 2021-07-09
LT3827005T (lt) 2022-11-10
CA3107556A1 (en) 2020-01-30
ZA202101092B (en) 2022-09-28
MX2021000966A (es) 2021-07-06
WO2020020939A1 (en) 2020-01-30
AU2019310889A1 (en) 2021-03-11
PH12021550143A1 (en) 2021-09-13
BR112021001270A2 (pt) 2021-04-20
MA53372A (fr) 2021-06-02
ECSP21010874A (es) 2021-03-31
JP2021531304A (ja) 2021-11-18
KR20210038909A (ko) 2021-04-08
DK3827005T3 (da) 2022-09-19
CO2021001925A2 (es) 2021-03-08
AU2019310889B2 (en) 2022-03-31
KR102603203B1 (ko) 2023-11-16
PL3827005T3 (pl) 2022-11-28
CN112739699A (zh) 2021-04-30
CA3107556C (en) 2022-10-25
NZ773053A (en) 2023-10-27
EA202190339A1 (ru) 2021-05-20
EP3827005A1 (en) 2021-06-02
CN112739699B (zh) 2023-11-28
PT3827005T (pt) 2022-11-04
HRP20221250T1 (hr) 2022-12-09
SG11202100575QA (en) 2021-02-25
HUE059824T2 (hu) 2023-01-28
EP3827005B1 (en) 2022-08-17
MA53372B1 (fr) 2022-10-31

Similar Documents

Publication Publication Date Title
PE20190475A1 (es) Inhibidores de cdk2/4/6
MX2021013110A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
PE20141404A1 (es) Derivados de tieno[3,2-d]pirimidina que tienen actividad inhibidora por las quinasas de las proteinas
PE20210406A1 (es) Inhibidores de inflamasoma nlrp3
MA51846A (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases
PE20190918A1 (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
PE20170693A1 (es) Derivados de imidazol pentaciclicos fusionados
PE20120418A1 (es) DERIVADOS DE PIRIDO[2,3-b]PIRAZINA COMO INHIBIDORES DE POLI (ADP-RIBOSA) POLIMERASA (PARP)
PE20090835A1 (es) Derivados de quinazolina como inhibidores de la pi3 quinasa
PE20140390A1 (es) Derivados de imidazo[1,2-b]piridazina e imidazo[4,5-b]piridina como inhibidores de jak
PE20081612A1 (es) Analogos de las pterinas
PE20090241A1 (es) Derivados de quinolina-carboxamida en calidad de antagonistas de p2y12
PE20170640A1 (es) Derivados de quinolizinona como inhibidores de pi3k
PE20170403A1 (es) COMPUESTOS DE IMIDAZO[4,5-c]QUINOLIN-2-ONA Y SU USO PARA TRATAR CANCER
PE20070021A1 (es) Compuestos triazolopiridinas como antagonistas de receptor canabinoide 1
PE20141010A1 (es) Derivados de piridin-2(1h)-ona utiles como medicamentos para el tratamiento de transtornos mieloproliferativos, rechazo de transplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias
AR064476A1 (es) Derivados de 1h-pirrolo[2, 3-b]piridina sustituidos, composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por a-raf, b-raf y/o por c-raf-1.
ES2564010T3 (es) Composición farmacéutica para tratar o prevenir el glaucoma
PE20121352A1 (es) Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
PE20140928A1 (es) Pirazolo[4,3-d]pirimidinas utiles como inhibidores de cinasas
PE20130184A1 (es) Compuesto heterociclico
PE20090049A1 (es) Derivados de piridopirimidina como moduladores de la actividad de pde 4
PE20091039A1 (es) IMIDAZO PIRAZINAS FUSIONADAS ARILO Y HETEROARILO [1,5-a] COMO INHIBIDORES DE LA FOSFODIESTERASA 10
PE20120120A1 (es) DERIVADOS DE 2H-PIRAZOLO[3,4-d]PIRIMIDINA-4,6(5H,7H)-DIONA, COMO INHIBIDORES DE PDE1